MARKET

ARAY

ARAY

Accuray Incorp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.200
-0.100
-4.35%
After Hours: 2.200 0 0.00% 16:01 05/18 EDT
OPEN
2.330
PREV CLOSE
2.300
HIGH
2.330
LOW
2.200
VOLUME
1.05M
TURNOVER
207.64K
52 WEEK HIGH
5.93
52 WEEK LOW
2.075
MARKET CAP
204.16M
P/E (TTM)
-15.5477
1D
5D
1M
3M
1Y
5Y
New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System, to accurately and efficiently treat a wi...
PR Newswire · 05/10 11:30
Down 20% in 4 Weeks, Here's Why Accuray (ARAY) Looks Ripe for a Turnaround
Accuray (ARAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks · 05/05 13:35
Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
Accuray Incorporated (NASDAQ: ARAY) announced today that its ClearRT™ helical fan-beam kVCT imaging capability for the Radixact® System has been selected as the winner of the "Best New Technology Solution for Oncology" award in the sixth annual MedTech Bre...
PR Newswire · 05/05 12:00
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 211 companies set new 52-week lows.
Benzinga · 05/03 16:20
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Zacks · 04/29 14:45
Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates
Accuray (ARAY) delivered earnings and revenue surprises of 83.33% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/27 22:35
BRIEF-Accuray Reports Q3 Loss Per Share $0.01
reuters.com · 04/27 22:17
Accuray Q3 EPS $(0.01) Beats $(0.04) Estimate, Sales $96.17M Miss $97.28M Estimate
Accuray (NASDAQ:ARAY) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. The company reported quarterly sales of $96.17 million which missed the analyst
Benzinga · 04/27 20:38
More
No Data
Learn about the latest financial forecast of ARAY. Analyze the recent business situations of Accuray Incorp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ARAY stock price target is 8.30 with a high estimate of 10.00 and a low estimate of 7.00.
High10.00
Average8.30
Low7.00
Current 2.200
EPS
Actual
Estimate
-0.05-0.04-0.02-0.01
Q4 2021
Q1 2022
    00
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 196
Institutional Holdings: 74.58M
% Owned: 80.37%
Shares Outstanding: 92.80M
TypeInstitutionsShares
Increased
48
6.72M
New
21
1.86M
Decreased
48
3.41M
Sold Out
13
2.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.89%
Healthcare Equipment & Supplies
-2.33%
Key Executives
President
Suzanne Winter
Chief Executive Officer/Director
Joshua Levine
Chief Financial Officer/Senior Vice President
Ali Pervaiz
Senior Vice President/Chief Administrative Officer
Patrick Spine
Senior Vice President/General Counsel/Secretary
Jesse Chew
Director
Mika Nishimura
Director
Byron Scott
Independent Director
Elizabeth Davila
Independent Director
James Hindman
Independent Director
Beverly Huss
Independent Director
Anne Le Grand
Independent Director
Richard Pettingill
Independent Director
Joseph Whitters
No Data
No Data
About ARAY
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The Company's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Webull offers kinds of Accuray Incorporated stock information, including NASDAQ:ARAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAY stock methods without spending real money on the virtual paper trading platform.